{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:38:14Z","timestamp":1792597094762,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.cll.2026.07.008","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:13:33Z","timestamp":1786493613000},"page":"769-783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing Clozapine Use Through Therapeutic Drug Monitoring\u2014Integrating Clinical and Laboratory Science Perspectives"],"prefix":"10.1016","volume":"46","author":[{"given":"Jessica M.","family":"Boyd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda J.","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan G.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert O.","family":"Cotes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cll.2026.07.008_bib1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/0957154X07070335","article-title":"The history of clozapine and its emergence in the US market: a review and analysis","volume":"18","author":"Crilly","year":"2007","journal-title":"Hist Psychiatry"},{"issue":"3","key":"10.1016\/j.cll.2026.07.008_bib2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF00606409","article-title":"Agranulocytosis during treatment with chlozapine","volume":"11","author":"Id\u00e4np\u00e4\u00e4n-Heikkil\u00e4","year":"1977","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.cll.2026.07.008_bib3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41398-021-01613-2","article-title":"Efficacy and safety of clozapine in psychotic disorders-a systematic quantitative meta-review","volume":"11","author":"Wagner","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"4","key":"10.1016\/j.cll.2026.07.008_bib4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000507638","article-title":"A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology","volume":"89","author":"de Leon","year":"2020","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.cll.2026.07.008_bib5","series-title":"The American psychiatric association practice guideline for the treatment of patients with schizophrenia","author":"American Psychiatric Association","year":"2020"},{"key":"10.1016\/j.cll.2026.07.008_bib6","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1176\/appi.ps.20250098","article-title":"A national analysis of facility-level clozapine availability in U.S. mental health services","volume":"76","author":"Bunting","year":"2025","journal-title":"Psychiatr Serv"},{"issue":"1","key":"10.1016\/j.cll.2026.07.008_bib7","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1186\/s12888-023-05176-y","article-title":"Long-term outcomes of delayed clozapine initiation in treatment-resistant schizophrenia: a multicenter retrospective cohort study","volume":"23","author":"Hatano","year":"2023","journal-title":"BMC Psychiatry"},{"issue":"1\u201302","key":"10.1016\/j.cll.2026.07.008_bib8","first-page":"9","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"10.1016\/j.cll.2026.07.008_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/a-1625-6388","article-title":"An International Adult Guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels","volume":"55","author":"de Leon","year":"2022","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"10.1016\/j.cll.2026.07.008_bib10","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19cs13169","volume":"81","author":"Schoretsanitis","year":"2020","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.cll.2026.07.008_bib11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/BF01046700","article-title":"Clinical pharmacokinetics of clozapine in chronic schizophrenic patients","volume":"34","author":"Cheng","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.cll.2026.07.008_bib12","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1056\/NEJM199103143241107","article-title":"Clozapine. A novel antipsychotic agent","volume":"324","author":"Baldessarini","year":"1991","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.cll.2026.07.008_bib13","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1080\/17425255.2021.1974400","article-title":"Therapeutic drug monitoring of clozapine in adults with schizophrenia: a review of challenges and strategies","volume":"17","author":"Molden","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"10.1016\/j.cll.2026.07.008_bib14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2165\/00003088-199324020-00005","article-title":"Pharmacokinetics and pharmacodynamics of clozapine","volume":"24","author":"Jann","year":"1993","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.cll.2026.07.008_bib15","first-page":"923","article-title":"Isolation and identification of clozapine metabolites in patient urine","volume":"29","author":"Schaber","year":"2001","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.cll.2026.07.008_bib16","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/FPC.0000000000000347","article-title":"PharmGKB summary: clozapine pathway, pharmacokinetics","volume":"28","author":"Thorn","year":"2018","journal-title":"Pharmacogenet Genom"},{"issue":"4","key":"10.1016\/j.cll.2026.07.008_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/schbul\/sbaf160","article-title":"CYP2D6 genotypes do not affect clozapine levels in a large, multicenter cohort: time has come to revise Food and Drug Administration\u2019s clozapine packet insert","volume":"52","author":"Schoretsanitis","year":"2026","journal-title":"Schizophr Bull"},{"issue":"6","key":"10.1016\/j.cll.2026.07.008_bib18","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/acps.13228","article-title":"Impact of smoking behavior on clozapine blood levels - a systematic review and meta-analysis","volume":"142","author":"Wagner","year":"2020","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"10.1016\/j.cll.2026.07.008_bib19","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JCP.0000000000001606","article-title":"The modernization of clozapine: a recapitulation of the past in the United States and the view forward","volume":"42","author":"Leung","year":"2022","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.cll.2026.07.008_bib20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.schres.2017.03.045","article-title":"Elevated clozapine levels associated with infection: a systematic review","volume":"192","author":"Clark","year":"2018","journal-title":"Schizophr Res"},{"issue":"1","key":"10.1016\/j.cll.2026.07.008_bib21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S2215-0366(25)00098-7","article-title":"Absolute neutrophil count and adverse drug reaction monitoring during clozapine treatment: consensus guidelines from a global Delphi panel","volume":"13","author":"Siskind","year":"2026","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"10.1016\/j.cll.2026.07.008_bib22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/FTD.0000000000001233","article-title":"Making clozapine therapeutic drug monitoring essential for optimal patient care","volume":"46","author":"Leung","year":"2024","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.cll.2026.07.008_bib23","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/FTD.0000000000001188","article-title":"A short turnaround of clozapine blood level results within 6 hours is essential for effective management of severely ill persons with treatment-resistant schizophrenia","volume":"46","author":"Vincent","year":"2024","journal-title":"Ther Drug Monit"},{"issue":"4","key":"10.1016\/j.cll.2026.07.008_bib24","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/FTD.0000000000001415","article-title":"Perceptions, use, and barriers of clozapine therapeutic drug monitoring in the United States: a multidisciplinary survey study","volume":"48","author":"Leung","year":"2026","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.cll.2026.07.008_bib25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/FTD.0b013e31815f4e72","article-title":"Clozapine and norclozapine concentrations in serum and plasma samples from schizophrenic patients","volume":"30","author":"Hermida","year":"2008","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.cll.2026.07.008_bib26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00007691-199906000-00014","article-title":"Clozapine monitoring: plasma or serum levels?","volume":"21","author":"Kaladjian","year":"1999","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.cll.2026.07.008_bib27","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/FTD.0000000000000478","article-title":"Clozapine and norclozapine concentrations in paired human plasma and serum samples","volume":"40","author":"Handley","year":"2018","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.cll.2026.07.008_bib28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.forsciint.2013.03.021","article-title":"Stability of some atypical antipsychotics in human plasma, haemolysed whole blood, oral fluid, human serum and calf serum","volume":"229","author":"Fisher","year":"2013","journal-title":"Forensic Sci Int"},{"issue":"2","key":"10.1016\/j.cll.2026.07.008_bib29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/acps.12673","article-title":"The significance of sampling time in therapeutic drug monitoring of clozapine","volume":"135","author":"Jakobsen","year":"2017","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"10.1016\/j.cll.2026.07.008_bib30","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1192\/bja.2022.71","article-title":"Therapeutic monitoring of plasma clozapine and N-desmethylclozapine (norclozapine): practical considerations","volume":"29","author":"Flanagan","year":"2023","journal-title":"BJPsych Adv"},{"issue":"4","key":"10.1016\/j.cll.2026.07.008_bib31","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1309\/AJCPW0TA8OBBNGCK","article-title":"Current and future applications of mass spectrometry to the clinical laboratory","volume":"136","author":"Strathmann","year":"2011","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.1016\/j.cll.2026.07.008_bib33","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/FTD.0000000000000777","article-title":"Comparison of novel immunoassay with liquid Chromatography\/Tandem mass spectrometry (LC-MS\/MS) for therapeutic drug monitoring of clozapine","volume":"42","author":"Buckley","year":"2020","journal-title":"Ther Drug Monit"},{"issue":"6","key":"10.1016\/j.cll.2026.07.008_bib34","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/jalm\/jfab062","article-title":"Multi-site evaluation of immunoassays for antipsychotic drug measurement in clinical samples","volume":"6","author":"Clarke","year":"2021","journal-title":"J Appl Lab Med"},{"issue":"1","key":"10.1016\/j.cll.2026.07.008_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3371\/CSRP.KEBE.070415","article-title":"Blood draw barriers for treatment with clozapine and development of a point-of-care monitoring device","volume":"12","author":"Kelly","year":"2018","journal-title":"Clin Schizophr Relat Psychoses Spring"},{"issue":"5","key":"10.1016\/j.cll.2026.07.008_bib36","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/PRA.0000000000000878","article-title":"Use of point-of-care testing devices for patients on clozapine: a literature review","volume":"31","author":"Whiston","year":"2025","journal-title":"J Psychiatr Pract"},{"key":"10.1016\/j.cll.2026.07.008_bib38","doi-asserted-by":"crossref","DOI":"10.1177\/20451253221094435","article-title":"Clozapine blood level assessment using a point-of-care device: feasibility and reliability","volume":"12","author":"Kamhi-Nesher","year":"2022","journal-title":"Ther Adv Psychopharmacol"},{"issue":"3","key":"10.1016\/j.cll.2026.07.008_bib39","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0269881121991567","article-title":"Point-of-care measurement of clozapine concentration using a finger-stick blood sample","volume":"35","author":"Taylor","year":"2021","journal-title":"J Psychopharmacol"},{"issue":"2","key":"10.1016\/j.cll.2026.07.008_bib40","first-page":"231","article-title":"Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients","volume":"148","author":"Perry","year":"1991","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.cll.2026.07.008_bib41","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3371\/1935-1232.10.3.163","article-title":"Guide to the management of clozapine-related tolerability and safety concerns","volume":"10","author":"Citrome","year":"2016","journal-title":"Clin Schizophr Relat Psychoses Fall"},{"issue":"1","key":"10.1016\/j.cll.2026.07.008_bib42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00702-014-1300-5","article-title":"Clinical applications of CYP genotyping in psychiatry","volume":"122","author":"Spina","year":"2015","journal-title":"J Neural Transm (Vienna)"},{"issue":"7","key":"10.1016\/j.cll.2026.07.008_bib43","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/17512433.2019.1617695","article-title":"A comprehensive review of the clinical utility of and a combined analysis of the clozapine\/norclozapine ratio in therapeutic drug monitoring for adult patients","volume":"12","author":"Schoretsanitis","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.cll.2026.07.008_bib44","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00007691-199408000-00006","article-title":"Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service","volume":"16","author":"Jerling","year":"1994","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.cll.2026.07.008_bib45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/14740338.2020.1698545","article-title":"The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy","volume":"19","author":"Costa-Dookhan","year":"2020","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"10.1016\/j.cll.2026.07.008_bib46","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10597-021-00847-0","article-title":"A comparison of attitudes, comfort, and knowledge of clozapine among two diverse samples of US psychiatrists","volume":"58","author":"Cotes","year":"2022","journal-title":"Community Ment Health J"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271226000788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271226000788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:40:22Z","timestamp":1792593622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271226000788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0272271226000788"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2026.07.008","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing Clozapine Use Through Therapeutic Drug Monitoring\u2014Integrating Clinical and Laboratory Science Perspectives","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2026.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}